SRF's HFC expansion contradicts prior guidance; AI timelines shift
Q1 FY27 is the best ever quarter with EBIT up 61% to ₹1,116 cr, but management's stance on HFC capacity and AI commercialization contradicts what was said six months ago.
What's new
- Q1 FY27 consolidated revenue ₹5,033 cr, EBIT ₹1,116 cr (up 61% YoY), PAT ₹759 cr (up 76% YoY).
- Chemicals revenue ₹2,315 cr (up 26% YoY) led by fluorochemicals; Films revenue ₹2,710 cr (up 42% YoY) on supply disruptions.
- Management commissioned a new HFC plant in Odisha, contradicting the January 2026 statement that no additional HFC capacity was possible.
Themes from the call
Demand
Chemicals showed broad-based growth led by fluorochemicals, though specialty recovery remains pocketed and back-loaded. Films benefited from panic buying but is expected to normalize.
Margins
Operational EBIT margin at 22.0%, aided by high utilisation and value-added mix; management expects seasonal moderation in Q2.
Capital allocation
Capex continues on Odisha, fluoropolymer, BOPET and film assets, but PVDF commissioning slipped and no aluminium foil expansion is planned.
Guidance watch
- Chemicals revenue growth of 15-20% for FY27, with management hoping to reach the upper end; specialty recovery stronger in H2.
- Films EBIT margins expected to normalise in Q2 but remain above the 8-12% historical range.
- AI commercialisation timing uncertain despite prior guidance of a launch in the coming year; now characterised as early days.
- Capacitor-grade BOPP revenue expected in Q1 FY27, near-full capacity by Q1-Q2 FY28.
Risk flags
- HFC capacity expansion contradicts prior stance, raising credibility concerns.
- AI revenue visibility reduced after management walked back launch timing.
- Seasonal normalization across refrigerants and films expected after an exceptional Q1.
- Chemours' design changes have pushed FPC/FPE commissioning out by several months.
Key quotes
-
"There is no additional capacity that SRF can put up; we have put out whatever we can."
— Sameer Kashyap, Management, January 2026 call -
"Post the commissioning of our new HFC plant in Odisha, we will be in the top three to four refrigerant gas manufacturers globally."
— Sameer Kashyap, prepared remarks, July 2026 call
The brief
SRF delivered its best ever quarter: Q1 FY27 revenue at ₹5,033 cr, operational EBIT up 61% to ₹1,116 cr and PAT up 76% to ₹759 cr. The chemicals segment grew 26%, driven by high HFC utilisation, while films surged 42% on supply disruptions. But the numbers are overshadowed by a credibility gap. In January, management told investors SRF had no additional HFC capacity to put up. This quarter, it announced the commissioning of a new HFC plant in Odisha, aiming to be a top-three global refrigerant producer. No explanation was given for the pivot. Similarly, AI commercialisation – which management said was on track for a launch in the coming year with one registration already done – is now described as 'still early days' with the innovator world 'cautious'. The back-pedalling reduces visibility into a key growth driver that analysts had pegged at $400-500 million in peak revenue. Guidance for FY27 remains: chemicals growth of 15-20%, with specialty recovery back-loaded to H2. Films margins should normalise but stay above the historical 8-12% range. Capacity additions – from BOPET to capacitor-grade BOPP to fluoropolymers – are progressing, but execution timelines have slipped. SRF is executing well in the short cycle; the question is whether the long-cycle promises carry the same weight.
A record quarter can't mask the gap between what management says and what it does. On HFC and AI, the road ahead looks different from what was painted.